Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Change in Receivables (2016 - 2025)

United Therapeutics' Change in Receivables history spans 17 years, with the latest figure at $52.5 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 184.0% year-over-year to $52.5 million; the TTM value through Dec 2025 reached $70.9 million, up 17625.0%, while the annual FY2025 figure was $70.9 million, 17625.0% up from the prior year.
  • Change in Receivables for Q4 2025 was $52.5 million at United Therapeutics, up from -$81.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $138.1 million in Q2 2023 and bottomed at -$85.9 million in Q1 2023.
  • The 5-year median for Change in Receivables is $11.5 million (2022), against an average of $9.6 million.
  • The largest annual shift saw Change in Receivables plummeted 858.82% in 2021 before it surged 4832.14% in 2023.
  • A 5-year view of Change in Receivables shows it stood at -$14.1 million in 2021, then increased by 19.86% to -$11.3 million in 2022, then soared by 279.65% to $20.3 million in 2023, then plummeted by 407.88% to -$62.5 million in 2024, then surged by 184.0% to $52.5 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Change in Receivables are $52.5 million (Q4 2025), -$81.6 million (Q3 2025), and $57.3 million (Q2 2025).